Ventyx Biosciences, Inc.
NASDAQ: VTYX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sheila K. Gujrathi
- Employees
- 81
- Headquarters
- San Diego, United States
- IPO year
- 2021
- Market cap
- $1.0B
- Website
- https://www.ventyxbio.com
Loading VTYX…
Loading profile data…Frequently asked questions about VTYX
What does Ventyx Biosciences, Inc. (VTYX) do?
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This comp...
Where does VTYX trade?
Ventyx Biosciences, Inc. (VTYX) trades on the NASDAQ Global Select.
What sector is VTYX in?
Ventyx Biosciences, Inc. (VTYX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ventyx Biosciences, Inc.?
Sheila K. Gujrathi is the chief executive officer of Ventyx Biosciences, Inc. (VTYX).
Where is Ventyx Biosciences, Inc. headquartered?
Ventyx Biosciences, Inc. is headquartered in United States.
Does VTYX pay a dividend?
Ventyx Biosciences, Inc. (VTYX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VTYX go public?
Ventyx Biosciences, Inc. (VTYX) completed its initial public offering in 2021.